394800.Kq
The company operates in the biotechnology and medical research sector, primarily generating revenue through pharmaceutical and medical research activities.
Business. The company operates in the biotechnology and medical research sector, primarily generating revenue through pharmaceutical and medical research activities.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the biotechnology and medical research sector, primarily generating revenue through pharmaceutical and medical research activities.
The company maintains a strong liquidity position, with a current ratio of 6.23 and cash and equivalents amounting to 8,142,114,540 KRW. The price-to-book ratio is 13.5, indicating a premium valuation relative to its book value. However, the company is currently unprofitable, with a return on equity of -22.93% and a return on assets of -18.24%.
The company's profitability is significantly below industry norms, as evidenced by its negative operating and net income. The operating income is -5,889,097,930 KRW, and the net income is -5,411,302,060 KRW. These figures suggest that the company is not generating sufficient revenue to cover its operating costs and is experiencing substantial losses.
The company's revenue is concentrated in a single segment, as disclosed in its financial statements. There is no indication of geographic diversification in the provided data, suggesting that the company's revenue is primarily derived from a single region. This concentration could pose a risk if the company's primary market experiences economic downturns or regulatory changes.
The company's growth trajectory is currently negative, with a significant decline in revenue and earnings. Analyst estimates suggest that the company's revenue is expected to increase to 19,000,000,000 KRW, but the actual revenue for the last period was 11,709,000,000 KRW. The mean EPS estimate is -66.00 KRW, while the last actual EPS was -171.00 KRW, indicating a continued decline in earnings.
The company's risk assessment indicates low liquidity and dilution risks. There are no immediate filing-based liquidity or dilution flags. The debt-to-equity ratio is 0.14, suggesting a relatively low level of leverage. However, the company's negative operating and free cash flows indicate potential challenges in maintaining its current financial position without external financing.
Recent events, as reflected in the financial data, show a continued decline in profitability and cash flow. The operating cash flow is -3,558,249,940 KRW, and the free cash flow is -5,772,427,970 KRW. These figures suggest that the company is not generating sufficient cash from operations to fund its capital expenditures and other operational needs.
- The company has a strong liquidity position with a current ratio of 6.23 and significant cash reserves.
- The company is currently unprofitable, with a return on equity of -22.93% and a return on assets of -18.24%.
- The company's revenue is concentrated in a single segment, posing potential risks if the primary market experiences downturns.
- The company's growth trajectory is negative, with declining revenue and earnings as indicated by analyst estimates and actual financial results.
- The company has low liquidity and dilution risks, but its negative cash flows suggest potential challenges in maintaining its financial position without external financing.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -66,00 |
| Revenue | —no estimate | —no estimate | 19,0B KRW |
| Operating income | —no estimate | —no estimate | -2,9B KRW |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- 394800.KQ Market data — financials · 2026-05-26
- 3Billion Inc Market data — analyst estimates · 2026-05-26